Reuters: Regulatory News: Bayer's Nexavar gets priority review as thyroid cancer drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

The Best Way to Manage your Money. Start using Mint today to set a budget, track your goals and do more with your money. From our sponsors

Bayer's Nexavar gets priority review as thyroid cancer drug Aug 27th 2013, 06:44 FRANKFURT, June 2 | Tue Aug 27, 2013 2:44am EDT FRANKFURT, June 2 (Reuters) - Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday. The U.S. Food and Drug Administration aims to complete the priority review within six months, rather than the standard review of about 10 months, Bayer said. Bayer and development partner Onyx Pharmaceuticals are seeking a wider use for Nexavar to include treatment of patients with thyroid cancer that returned despite previous surgery and treatment with radioactive iodine, a group with a particularly poor prospect of survival. Nexavar is already approved to treat liver as well as kidney cancer and it is also being tested on breast cancer patients.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions